CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK ‌ R Mina, B Dhakal, J San-Miguel, N Lendvai, M Vogel, K Li, D Chen, N Patel, H Einsele, J Martinez-Lopez

Ստացեք ամբողջական տեքստը

P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING... ‌ H. Einsele, B. Dhakal, R. Potluri, J. Schecter, W. Deraedt, N. Lendvai, A. Slaughter, C. Lonardi, S. Nair, J. He, J. Voelker, P. Cost, S. Valluri, F. Yalniz, L. Pacaud, K. Yong

Ստացեք ամբողջական տեքստը

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE ‌ B. Dhakal, H. Einsele, R. Potluri, J. Schecter, W. Deraedt, N. Lendvai, A. Slaughter, C. Lonardi, S. Nair, J. He, N. Joseph, P. Cost, S. Valluri, F. Yalniz, L. Pacaud, K. Yong

Ստացեք ամբողջական տեքստը

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES... ‌ H. Einsele, B. Dhakal, J. M. Schecter, T. Roccia, W. Deraedt, N. Lendvai, A. Slaughter, C. Lonardi, K. Connors, K. Qi, A. Londhe, R. Carson, J. Voelker, P. Cost, S. Valluri, E. Florendo, L. Pacaud, K. Yong

Ստացեք ամբողջական տեքստը